Cuprina Holdings Shares Soar 48% in Premarket Trading Following Recent FDA Clearance
Summary
Cuprina Holdings (CUPR) is experiencing a significant premarket surge, with shares up 48% to $5.85. This strong positive momentum likely reflects investor reaction to the company's recent U.S. FDA 510(k) clearance for its MEDIFLY Maggots on June 15th, as well as its successful regaining of Nasdaq compliance on June 12th. Absci Corporation (ABSI) is also seeing notable premarket gains, up 18%.
At the time of this announcement, CUPR was trading at $5.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $1.76 to $76.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.